T cell responses to SARS-CoV-2 vaccination in people with multiple sclerosis differ between disease-modifying therapies
Preprint
Abstract
Immune responses in people with multiple sclerosis (pwMS) on disease-modifying therapies (DMTs) have been of significant interest throughout the COVID-19 pandemic. Lymphocyte-targeting immunotherapies including anti-CD20 treatments and sphingosine-1-phosphate receptor (S1PR) modulators attenuate antibody responses after vaccination. Evaluation of cellular responses after vaccination is therefore of particular importance in these populations. In this study, we analysed CD4 and CD8 T cell functional responses to SARS-CoV-2 spike peptides in healthy controls and pwMS on five different DMTs by flow cytometry. Although pwMS on anti-CD20 and S1PR therapies had low antibody responses after both 2 and 3 vaccine doses, T cell responses in pwMS on anti-CD20 therapies were preserved after a third vaccination, even when additional anti-CD20 treatment was administered between vaccine doses 2 and 3. PwMS taking S1PR modulators had low detectable T cell responses in peripheral blood. CD4 and CD8 T cell responses to SARS-CoV-2 variants of concern Delta and Omicron were lower than to the ancestral Wuhan-Hu-1 variant. Our results indicate the importance of assessing both cellular and humoral responses after vaccination and suggest that even in the absence of robust antibody responses vaccination can generate immune responses in pwMS.Keywords
This publication has 49 references indexed in Scilit:
- COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic reviewMultiple Sclerosis and Related Disorders, 2021
- Incidence and Risk of Infection Associated With Fingolimod in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of 8,448 Patients From 12 Randomized Controlled TrialsFrontiers in Immunology, 2021
- Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple SclerosisAnnals of Neurology, 2021
- Immune determinants of COVID-19 disease presentation and severityNature Medicine, 2021
- Correlates of protection against SARS-CoV-2 in rhesus macaquesNature, 2020
- Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19Acta Pharmacologica Sinica, 2020
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable TherapiesJAMA Neurology, 2020
- Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJAMA, 2019
- Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculationJournal of Neuroinflammation, 2017
- Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapyMultiple Sclerosis Journal, 2013